oratecan
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2010 (NCT01463982)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Multidrug resistance protein 3INHIBITOR
ABCB4 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- oratecan
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02250157 | Phase 1 | Sep 1, 2014 | Athenex, Inc. |
| NCT01463982 | Phase 1 | Dec 1, 2010 | Hanmi Pharmaceutical |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Athenex, Inc. | For profit | 1 | 1 | 1 | 2014 |
| Hanmi Pharmaceutical | For profit | 1 | 1 | 1 | 2010 |
2 organizations
Page 1 / 1